Avory & Company Trims Omnicell Position Following Q1 Recovery

Avory & Company, LLC has reduced its holdings in Omnicell (NASDAQ: OMCL), selling 156,571 shares for an estimated $6.55 million. The transaction, disclosed in a recent SEC filing, significantly lowers the firm's exposure to the healthcare automation provider. The divestment follows a period of volatility for Omnicell, which has seen its shares decline 68% since 2021. However, the company has shown signs of recent recovery, with its stock price rising 47.6% over the last twelve months, outperforming the S&P 500 by 18.45 percentage points. According to the filing, the sale reduced Omnicell's weight in Avory & Company's reportable assets under management from 8.48% to 3.33%. The fund now holds 77,137 shares, valued at approximately $2.57 million, which removes the stock from the firm's top five holdings. Omnicell continues to scale its integrated automation and software solutions for medication management, generating over $1.20 billion in annual revenue. The company's recent Q1 earnings report highlighted a revenue increase of 15% year-over-year to $310 million, with net income reaching $11 million, a sharp reversal from the $7 million loss reported in the prior year. While the recent earnings beat provides a positive signal regarding the company's operational health, the decision by Avory & Company to trim its position suggests a cautious approach to the stock's long-term recovery trajectory.